Innovations in HIV prevention and treatment
Janssen is exploring innovative applications of our HIV medicines to improve the treatment and prevention in areas which are hard to reach. For example, we’re looking for ways to reduce the frequency of dosing. We’re also working in collaboration with non-profit organizations to research new pathways to prevent HIV infection through injectable formulations and microbicidal rings.
Prevention as treatment
We’ve entered into an agreement with PATH (Programme for Appropriate Technology in Health), an international non-profit organization which improves global health with a view to the early development of means of preventing exposure (PrEP or Pre-Exposure Prophylaxis) to an HIV infection. PrEP is an HIV prevention strategy which involves the use of antiretroviral medicines to reduce the risk of HIV infection in healthy uninfected people who are at risk of catching the virus.
Prevention of sexual transmission of HIV
Janssen works together with the International Partnership for Microbicides (IPM), a non-profit organization dedicated to developing new HIV prevention technologies for women. The agreement is intended for the development of sexual and reproductive health products which contain antiretroviral drugs to prevent the sexual transmission of HIV. Read more about this partnership here.